Moderna Vaccine has completed its final stage clinical trials in Europe, UK and the United States (US). As a result, the Covid-19 mRNA-1273 vaccine has 94% efficacy against covid-19.
Company said that, none of the volunteers suffered from side effects when being vaccinated. Through this data Moderna will apply for emergency use permits to the UK, US and European health authorities.
Quoting the Guardian, Moderna hopes to obtain certainty of approval for use on December 17, 2020.
Moderna already raised $2.48 billion
Massachusetts-based pharmaceutical company Moderna has received $ 2.48 billion in funding from the US government, an important part of the Trump administration’s Operation Warp Speed, an operation to accelerate vaccine discovery.
Thus, US will get this vaccine first. Moderna targets to produce 20 million doses of vaccine by the end of this year for US citizens. Moderna hopes to produce 500 million to 1 billion doses of vaccine by 2021 for distribution globally.
Moderna’s final phase clinical trial involved 30,000 volunteers in the US, half of whom received the Moderna vaccine and half received a placebo (fake vaccine). In this trial 195 people fell ill. 30 people became seriously ill and one died, but none of them were given the Moderna vaccine.
The trial involved people at lowest risk
The trial included a large number of people in the lowest risk groups. There are 7,000 people over the age of 65 and more than 5,000 young people with chronic diseases. Namely diabetes, severe obesity and heart disease.
The study involved 11,000 people from ethnic black, Asian and minority communities. The selection of this community is due to 37%, the same proportion as the US population. Even so, there is no release of complete data.
“This positive primary analysis confirms the ability of our vaccine to prevent Covid-19 disease with an efficacy of 94.1% and, most importantly, the ability to prevent severe Covid-19 disease,” said Stéphane Bancel, CEO of Moderna.
“We believe our vaccine will into new and sophisticated tools that can change the course of this pandemic and help prevent serious illness, hospitalizations and deaths. ”
Moreover, Azra Ghani, professor of infectious disease epidemiology at Imperial College London, said the other good news is that nobody given the Moderna vaccine develops serious disease.
“While this does not exclude some risk of severe disease after vaccination given the relatively small number of severe cases, these results indicate a very high (> 85%) efficacy against this end point,” he said.